Special Issue "New Developments of Natural Killer (NK) Cells in Immunotherapy"

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 15 March 2020.

Special Issue Editor

Dr. Jacques Zimmer
E-Mail Website
Guest Editor
Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, 29 rue Henri Koch 4354, Luxembourg
Interests: natural killer cells; immunotherapy; MAIT cells; HLA class I deficiency

Special Issue Information

Dear Colleagues,

Most of the first natural killer (NK) cell papers in the 1970s described a cytolytic effect on various tumor cell lines, so the idea of using NK cells in immunotherapy of cancer rapidly came up. However, success in the clinical settings was very limited. Four decades later, the therapeutic possibilities given by these cells have reached an unanticipated level of sophistication and diversity that goes in parallel with a steadily increasing knowledge about NK cell biology. Even if they are mistakenly less considered than chimeric antigen receptor (CAR)-T cells, NK cells have become a serious option for cancer treatment, although by far not all problems are resolved. The interest of the scientific community is highlighted by the increasing number of reviews about this topic. In the present Special Issue of Cells, experts in the field will describe the state-of-the-art in NK cell-based immunotherapy in 2020, based on their own expertise and on literature published in recent years.

Dr. Jacques Zimmer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural killer cells
  • immunotherapy
  • leukemia and lymphoma
  • solid tumors
  • infectious diseases
  • tumor microenvironment

Published Papers

This special issue is now open for submission, see below for planned papers.

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Author: Winfried S. Wels,  Oberoi et al
Tentative Title: Directed differentiation of mobilized HSCs into functional NK cells with enhanced antitumor activity

Author: Rajalingam Raja

Tentative Title: Review - how the polymorphic interactions of KIR-HLA combinations could control the therapeutic antibody dependent NK cell-mediated response to cancer

Author: Genny Del Zotto1, *Flavia Buccella2, Sara Gabrielli2, Barbara Canonico2, Marco Artico3, Stefano Papa2, Loris Zamai2,4

Tentative Title: Understanding the Synergy of Nkp46 and Co-Activating Signals in Various Nk Subpopulations: Paving the Way for More Successful Nk-Cell-Based Immunotherapy

Back to TopTop